Reslizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | IL-5 |
Clinical data | |
Trade names | Cinquil |
Identifiers | |
ATC code | R03DX08 (WHO) |
ChemSpider | none |
(verify) |
Reslizumab (trade name Cinqair) is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract.[1] The FDA approved reslizumab for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older on March 23, 2016. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.[2]
References
- ↑ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666.
- ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491980.htm
|
This article is issued from Wikipedia - version of the Monday, March 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.